The currently used agents all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) directly target PML-RARα oncoprotein and dramatically improve the clinical outcome of APL patients [3–13]. This evidence concerns the gene PML and acute promyelocytic leukemia.